First-line tagraxofusp leads to durable responses and prolonged survival in adults with blastic plasmacytoid dendritic cell neoplasm regardless of fitness level | Synapse
January 17, 2026Open Access
First-line tagraxofusp leads to durable responses and prolonged survival in adults with blastic plasmacytoid dendritic cell neoplasm regardless of fitness level
Key Points
To evaluate the effectiveness of tagraxofusp as a first-line treatment in blastic plasmacytoid dendritic cell neoplasm.
Administered tagraxofusp to adults diagnosed with blastic plasmacytoid dendritic cell neoplasm.
Assessed patient responses and survival rates.
Included patients with varying fitness levels.
Patients showed durable responses to tagraxofusp treatment.
Prolonged survival was observed regardless of fitness level.